ASCO’s first-in-human studies center on solid tumor surface antigens 

The translational trends at this year’s ASCO conference are converging on new and selective ways to target cell surface receptors on solid tumors. The goals are to make the industry’s most transformational modalities more effective against solid tumors and find new ways to treat the solid tumor types that haven’t been well-served by more traditional mechanisms.

BioCentury’s analysis of the first-in-human clinical trials presented at the American Society of Clinical Oncology (ASCO) conference this year identified 124 therapies being tested in people for the first time. The analysis includes both first-in-human trial readouts and descriptions of trials in progress, but excludes data from expansion cohorts when initial data were previously presented. ...